首页> 外国专利> Intermediate compound for the preparation of conjugates comprising auristatin derivatives and a linker

Intermediate compound for the preparation of conjugates comprising auristatin derivatives and a linker

机译:用于制备包含澳瑞他汀衍生物和接头的缀合物的中间体化合物

摘要

A conjugate having the formula: LU-DF or a pharmaceutically acceptable salt thereof, wherein: LU- is a linker unit comprising a functional group capable of binding to a ligand or an antibody, and DF is a group having the following formula: ** Formula ** wherein: independently at each location: R2 is selected from H and C1-C8 alkyl; R3 is selected from H, C1-C8 alkyl, C3-C8 carbocycle, aryl, C1-C8 alkylaryl, C1-C8 alkyl- (C3-C8 carbocycle), C3-C8 heterocycle and C1-C8 alkyl- (C3-C8 heterocycle) ); R4 is selected from H, C1-C8 alkyl, C3-C8 carbocycle, aryl, C1-C8 alkylaryl, C1-C8 alkyl- (C3-C8 carbocycle), C3-C8 heterocycle and C1-C8 alkyl- (C3-C8 heterocycle) ); R5 is selected from H and methyl; or: R4 and R5 together form a carbocyclic ring having the formula - (CRaRb) n-, wherein Ra and Rb are independently selected from H, C1-C8 alkyl and C3-C8 carbocycle and n is selected from 2, 3, 4, 5 and 6; R6 is selected from H and C1-C8 alkyl; R7 is selected from H, C1-C8 alkyl, C3-C8 carbocycle, aryl, C1-C8 alkylaryl, C1-C8 alkyl- (C3-C8 carbocycle), 3 C3-C8 heterocycle and C1-C8 alkyl- (C3- heterocycle) C8); each R8 is independently selected from H, OH, C1-C8 alkyl, C3-C8 carbocycle and O- (C1-C8 alkyl); R9 is selected from H and C1-C8 alkyl; R10 is selected from aryl and C3-C8 heterocycle; Z is O, S, NH or NR 12, wherein R 12 is C 1 -C 8 alkyl; R11 is selected from H, C1-C20 alkyl, - (R13O) m-R14 and - (R13O) m-CH (R15) 2; m is an integer comprised from 1 to 1000; R 13 is C 2 -C 8 alkyl; R14 is H or C1-C8 alkyl; each occurrence of R15 is independently H, COOH, - (CH2) n-N (R16) 2, - (CH2) n- SO3H or - (CH2) n-SO3- C1-C8 alkyl; each occurrence of R16 is independently H, C1-C8 alkyl or - (CH2) n -COOH; and n is an integer between 0 and 6.
机译:具有下式的缀合物:LU-DF或其药学上可接受的盐,其中:LU-是包含能够与配体或抗体结合的官能团的接头单元,并且DF是具有下式的基团:**式**其中:在每个位置独立地:R 2选自H和C 1 -C 8烷基; R3选自H,C1-C8烷基,C3-C8碳环,芳基,C1-C8烷基芳基,C1-C8烷基-(C3-C8碳环),C3-C8杂环和C1-C8烷基-(C3-C8杂环) )); R4选自H,C1-C8烷基,C3-C8碳环,芳基,C1-C8烷基芳基,C1-C8烷基-(C3-C8碳环),C3-C8杂环和C1-C8烷基-(C3-C8杂环) )); R5选自H和甲基;或:R4和R5一起形成具有式-(CRaRb)n-的碳环,其中Ra和Rb独立地选自H,C1-C8烷基和C3-C8碳环,并且n选自2、3、4 5和6; R6选自H和C1-C8烷基; R7选自H,C1-C8烷基,C3-C8碳环,芳基,C1-C8烷基芳基,C1-C8烷基-(C3-C8碳环),3个C3-C8杂环和C1-C8烷基-(C3-杂环) )C8);每个R 8独立地选自H,OH,C 1 -C 8烷基,C 3 -C 8碳环和O-(C 1 -C 8烷基); R9选自H和C1-C8烷基; R10选自芳基和C3-C8杂环; Z为O,S,NH或NR 12,其中R 12为C 1 -C 8烷基; R11选自H,C1-C20烷基,-(R13O)m-R14和-(R13O)m-CH(R15)2; m是1〜1000的整数。 R 13为C 2 -C 8烷基; R14为H或C1-C8烷基; R15的每次出现独立地为H,COOH,-(CH2)n-N(R16)2,-(CH2)n-SO3H或-(CH2)n-SO3-C1-C8烷基; R16的每次出现独立地为H,C1-C8烷基或-(CH2)n-COOH; n是0到6之间的整数。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号